Capital Midwest Fund

US biopharma firm ProNAi lands $60M in Series D funding to fight lymphoma

Michigan, US-based biopharmaceutical firm ProNAi Therapeutics landed $60 million in its Series D funding round led by Vivo Capital to advance its cancer treatment drugs to the second phase of clinical trials.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics